FASN and prostate carcinoma: miR-342 can inhibit the expression of SREBP, resulting in down-regulation of FASN and 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) and inhibition of FA biosynthesis in prostate cancer cells [75].